Table 1. Distribution of Baseline Characteristics of Patients, Tumor Stage, and COVID-19 Variables by Major Outbreak Grouping.
| Characteristic | Outbreak, No. (%) | P valuec | |
|---|---|---|---|
| 1st (n = 1626)a | 2nd (n = 1008)b | ||
| Country | |||
| United Kingdom | 552 (33.9) | 393 (39.0) | <.001 |
| Spain | 464 (28.5) | 175 (17.4) | |
| Italy | 418 (25.7) | 396 (39.3) | |
| Germany, Belgium, and France | 192 (11.8) | 44 (4.4) | |
| Sex | |||
| Male | 849 (52.3) | 541 (53.7) | .51 |
| Female | 773 (47.7) | 467 (46.3) | |
| Missingd | 4 | 0 | |
| Age, y | |||
| <65 | 641 (39.7) | 442 (43.9) | .03 |
| ≥65 | 974 (60.3) | 564 (56.1) | |
| Missingd | 11 | 2 | |
| Comorbidities | |||
| 0-1 | 833 (51.2) | 581 (57.6) | .001 |
| ≥2 | 793 (48.8) | 427 (42.4) | |
| Tumor stage | |||
| Local/locoregional | 817 (53.6) | 420 (43.9) | <.001 |
| Advanced | 708 (46.4) | 536 (56.1) | |
| Missingd | 101 | 52 | |
| Tumor status | |||
| Remission/nonmeasurable disease | 521 (32.8) | 339 (34.1) | .47 |
| Active cancer | 1069 (67.2) | 654 (65.9) | |
| Missing | 36 | 15 | |
| Anticancer therapy | |||
| No | 775 (48.7) | 438 (47.2) | .48 |
| Yes | 816 (51.3) | 489 (52.8) | |
| Missingd | 35 | 81 | |
| COVID-19 complications | |||
| No | 888 (54.6) | 666 (66.1) | <.001 |
| Yes | 738 (45.4) | 342 (33.9) | |
| COVID-19 therapy | |||
| No | 622 (38.3) | 507 (50.3) | <.001 |
| Yes | 1004 (61.7) | 501 (49.7) | |
| Hospitalization | |||
| Not required | 290 (17.9) | 303 (30.5) | <.001 |
| Required | 969 (59.8) | 418 (42.1) | |
| Preexisting | 361 (22.3) | 272 (27.4) | |
| Missingd | 6 | 15 | |
a
The first outbreak occurred from February to June 2020.
b
The second outbreak occurred from July 2020 to February 2021.
c
Values obtained via χ2 test for the comparison across the 2 major outbreaks; missing data were excluded from the proportions’ estimation. Primary tumor information according to the 2 major outbreaks is available in eTable 5 in the Supplement.
d
Proportions have been computed after the exclusion of missing data from the denominator.